Viagra, 50 mg 2 pc

VIAGRA is a drug for the treatment of erectile dysfunction. It acts on the natural mechanisms of erection. It is used in men suffering from erectile dysfunction of various origins (vascular, nervous erectile dysfunction).

Sildenafil is a potent and selective inhibitor of cGMP-specific phosphodiesterase type 5 (FDE5).
The physiological mechanism of penile erection involves the release of nitric oxide (NO) in the cavernous body during sexual stimulation.

Nitric oxide activates the enzyme guanylate cyclase, which leads to increased levels of cyclic guanosine monophosphate (cGMP), relaxing the smooth muscles of the cavernous body and increasing blood flow in the penis.

Sildenafil has no direct relaxant effect on the isolated human cavernous body, but actively enhances the relaxant effect of NO on this tissue by inhibiting FDE5, which is responsible for the breakdown of cGMP in the cavernous body.

In sexual arousal, local release of NO under the influence of sildenafil leads to inhibition of FDEF5 and increases cGMP levels in the corpora cavernosa, resulting in relaxation of smooth muscles and increased blood flow in the corpora cavernosa.

The prerequisite for the effectiveness of sildenafil is sexual stimulation.

Indications

Treatment of erectile dysfunction, characterized by the inability to achieve or maintain a penile erection sufficient for satisfactory sexual intercourse.

Viagra is effective only in the presence of sexual stimulation.

Pharmacological effect

VIAGRA is a drug for the treatment of erectile dysfunction – erectile dysfunction. Acts on the natural mechanisms of erection. It is used in men suffering from erectile dysfunction of various origins (vascular, nervous erection disorders).

Sildenafil is a potent and selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5).
The physiological mechanism of penile erection involves the release of nitric oxide (NO) in the corpus cavernosum upon sexual stimulation.

Nitric oxide activates the enzyme guanylate cyclase, which leads to increased levels of cyclic guanosine monophosphate (cGMP), relaxation of the smooth muscles of the corpus cavernosum and increased blood flow in the penis.

Sildenafil does not have a direct relaxing effect on the isolated human corpus cavernosum, but actively enhances the relaxing effect of NO on this tissue by inhibiting PDE5, which is responsible for the breakdown of cGMP in the corpus cavernosum.

During sexual arousal, local release of NO under the influence of sildenafil leads to inhibition of PDE5 and an increase in the level of cGMP in the corpus cavernosum, resulting in relaxation of smooth muscles and increased blood flow in the corpus cavernosum.

A prerequisite for the effectiveness of sildenafil is sexual stimulation.

Special instructions

To diagnose erectile dysfunction, determine its possible causes and select adequate treatment, it is necessary to obtain a complete medical history and conduct a thorough physical examination.

Treatments for erectile dysfunction should be used with caution in patients with anatomical deformation of the penis (angulation, cavernous fibrosis, Peyronie’s disease), or in patients with risk factors for the development of priapism (sickle cell anemia, multiple myeloma, leukemia).

Medicines intended to treat erectile dysfunction should not be prescribed to men for whom sexual activity is undesirable.

Active ingredient

Sildenafil

Composition

Active substance:

sildenafil (as sildenafil citrate) 50 mg;

excipients:

microcrystalline cellulose,

calcium hydrogen phosphate (anhydrous),

sodium croscarmellose,

magnesium stearate,

film coating Opadry blue and Opadry transparent.

Pregnancy

The drug is taken orally.
For most patients, the recommended dose is 50 mg; The drug is taken if necessary approximately 1 hour before sexual activity. Taking into account effectiveness and tolerability, the dose can be increased to 100 mg or reduced to 25 mg.

The maximum recommended dose is 100 mg.
The maximum recommended frequency of use is 1 time/day.

Contraindications

– Hypersensitivity to any component of the drug.
– Use in patients receiving continuous or intermittent nitric oxide donors, organic nitrates or nitrites in any form.
– Age up to 18 years.
– Not intended for use in women.

With caution: anatomical deformation of the penis (including angulation, cavernous fibrosis or Peyronne’s disease), diseases predisposing to the development of priapism (such as sickle cell anemia, multiple myeloma, leukemia, thrombocythemia), diseases accompanied by bleeding, exacerbation of peptic ulcer disease, hereditary retinitis pigmentosa, heart failure, unstable angina, myocardial infarction, stroke or life-threatening arrhythmias in the last 6 months, arterial hypertension (BP > 170/100 mm Hg) or hypotension (BP < 90/50 mm Hg).

Side Effects

Adverse effects are usually transient and mild or moderate. The incidence of adverse events increases with increasing dose.

From the body as a whole: asthenia, pain, abdominal pain, back pain, infection, flu-like syndrome.

From the cardiovascular system: vasodilation (a side effect recorded in clinical studies).

From the digestive system: diarrhea, nausea.

From the musculoskeletal system: joint pain, muscle pain.

From the central nervous system and peripheral nervous system: dizziness (a side effect recorded in clinical studies), increased muscle tone, insomnia.

From the respiratory system: nasal congestion, pharyngitis, rhinitis (a side effect registered in clinical studies), sinusitis, respiratory tract infections, respiratory dysfunction.

Dermatological reactions: rash.

From the senses: changes in vision: mild and transient, mainly changes in the color of objects, as well as increased perception of light and blurred vision (a side effect recorded in clinical studies), conjunctivitis.

From the urinary system: urinary tract infections.

From the reproductive system: dysfunction of the prostate gland.

When using the drug in doses higher than recommended, side effects were similar to those noted above, but were usually more common.

Adverse events reported during post-marketing use are listed below.

From the cardiovascular system: arterial hypotension, fainting, tachycardia, palpitations.

From the digestive system: vomiting (a side effect recorded in clinical studies).

From the reproductive system: prolonged erection and/or priapism.

From the senses: pain in the eyes, redness of the eyes.

Other: allergic reactions.

Storage conditions

In a dry place, at a temperature not exceeding 30 °C

Shelf life

5 years

Manufacturer

Fareva Amboise, France